Hologic (NASDAQ: HOLX) has recently received a number of price target changes and ratings updates:

  • 8/9/2017 – Hologic was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/9/2017 – Hologic had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $45.00 price target on the stock, down previously from $50.00.
  • 8/9/2017 – Hologic had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $51.00 price target on the stock, down previously from $53.00.
  • 8/4/2017 – Hologic was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Hologic’s third-quarter 2017 performance was quite promising with revenues and earnings beating the Zacks Consensus Estimate. The company’s top-line growth was led by strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales were driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing. Also, the company’s strong cash position is another encouraging factor. On the flip side, Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges.”
  • 8/3/2017 – Hologic had its price target lowered by analysts at Deutsche Bank AG from $51.00 to $49.00. They now have a “buy” rating on the stock.
  • 8/3/2017 – Hologic had its price target lowered by analysts at Royal Bank Of Canada from $50.00 to $45.00. They now have a “sector perform” rating on the stock.
  • 8/3/2017 – Hologic was downgraded by analysts at Goldman Sachs Group, Inc. (The) from a “conviction-buy” rating to a “buy” rating. They now have a $47.00 price target on the stock, down previously from $48.00.
  • 8/3/2017 – Hologic had its price target lowered by analysts at Barclays PLC from $53.00 to $51.00. They now have an “overweight” rating on the stock.
  • 8/2/2017 – Hologic was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/1/2017 – Hologic had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They wrote, “FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 8/1/17. The number of digital breast tomosynthesis (DBT) units increased by 106 during July which represents a (2.8%) Y/ Y decrease and a 2.2% sequential increase. DBT unit penetration increased to 27.4% from 27.0% last month and facility penetration increased to 40.8% from 40.0% last month. While this is a bit of an improvement from last month, the MQSA data seems to indicate that the slower Breast Imaging growth seen in F2Q17 has continued. We note that HOLX’s 3D mammography sales are less than 13% of its sales.””
  • 7/25/2017 – Hologic was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/21/2017 – Hologic had its “neutral” rating reaffirmed by analysts at Bank of America Corporation. They now have a $48.00 price target on the stock, up previously from $44.00.
  • 7/17/2017 – Hologic had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $53.00 price target on the stock, up previously from $50.00.
  • 7/14/2017 – Hologic had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $51.00 price target on the stock.
  • 7/14/2017 – Hologic had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.
  • 7/12/2017 – Hologic was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Hologic witnessed a lackluster performance at its Diagnostics segment in the last reported quarter. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges. On a positive note, the company has been registering strong top line growth in recent times driven by strength in molecular diagnostics, GYN Surgical and Breast Health businesses. The company's raised guidance for fiscal 2017 indicates that this growth momentum should continie through rest of the year.  In fact, the recent European approval for the company's new Panther system should boost growth in the coming quarter. For the last three months, Hologic has been trading above the broader Medical Instruments industry in terms of price. Hologic’s strong cash position is another encouraging factor.”
  • 6/28/2017 – Hologic had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $49.00 price target on the stock.

Shares of Hologic, Inc. (NASDAQ:HOLX) traded down 2.45% during mid-day trading on Thursday, hitting $37.39. 3,691,144 shares of the stock were exchanged. The company has a market capitalization of $10.49 billion, a PE ratio of 13.93 and a beta of 0.90. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The firm has a 50-day moving average price of $44.21 and a 200 day moving average price of $42.94.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.51 EPS. On average, equities research analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.

In other news, insider Peter J. Valenti III sold 10,005 shares of the stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the sale, the insider now owns 20,994 shares of the company’s stock, valued at approximately $911,979.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence M. Levy sold 9,076 shares of the stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total value of $388,452.80. Following the completion of the sale, the director now directly owns 43,165 shares of the company’s stock, valued at approximately $1,847,462. The disclosure for this sale can be found here. In the last three months, insiders sold 60,627 shares of company stock valued at $2,632,911. 0.79% of the stock is currently owned by insiders.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.